Clinical trials: Influenza B
Viral Lung Infection and Acute Respiratory Failure
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
The purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV/ECMO.
- Trial name
- TILIA (NCT05624450)
- Testing
- Tozorakimab
- Where
- 471 sites in United States, Argentina and 37 more
- Volunteers
- 3,527 people
- Sponsor
- AstraZeneca
Influenza
Phase I Clinical Trial of Influenza Vaccine (Split Virion), Inactivated (High Dose)
This is a randomized, double-blind, active-controlled Phase I clinical trial to evaluate the safety and immunogenicity of Influenza Vaccine (Split Virion), Inactivated (High Dose) developed by Sinovac.
- Trial name
- NCT07737106
- Testing
- Influenza Vaccine (Split Virion), Inactivated (High Dose), Influenza Vaccine (Split Virion), Inactivated
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Influenza, Human, Infections
Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults
This Phase 1, randomized, observer-blind, dose-ranging clinical study is evaluating 6 different formulations of MF59-adjuvanted and non-adjuvanted H2N3 influenza vaccine.
- Conditions
- Influenza, Human, Infections, Respiratory Tract Infections, Virus Diseases
- Trial name
- NCT05875961
- Testing
- Low dose A/H2N3c + standard dose MF59, Intermediate dose A/H2N3c + standard dose MF59, High dose A/H2N3c + standard dose MF59
- Where
- 7 sites in United States, Philippines
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
A Phase IV Clinical Trial of Influenza Vaccine (Split Virion), Inactivatedin (Anflu®) Pregnant Women (AnFLU-PREG)
A phase IV clinical trial of Influenza Vaccine (Split Virion), Inactivated (Anflu®) developed by Sinovac Biotech Co., Ltd will be conducted in pregnant women.
- Trial name
- NCT07832201
- Testing
- Anflu®, Vaxigrip®
- Where
- 6 sites in China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Influenza, Human
A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above
The purpose of this study is to assess the reactogenicity, safety and immune response of GlaxoSmithKline's (GSK) messenger RNA (mRNA)-based multivalent seasonal influenza vaccine candidates administered in healthy younger and…
- Trial name
- NCT07204964
- Testing
- Flu mRNA (Formulation B1), Flu mRNA (Formulation B3), Flu mRNA(Formulation A)
- Where
- 17 sites in United States, Belgium
- Volunteers
- 971 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human
A Study on the Efficacy of a Vaccine Against Influenza in Adults ≥65 Years of Age
This study will compare an investigational mRNA flu vaccine with a licensed flu vaccine in adults 65 years of age and older. Participants will receive one injection and will be followed during the flu season.
- Trial name
- NCT07805707
- Testing
- mRNA Seasonal Flu vaccine, Licensed Influenza Vaccine
- Where
- 163 sites in United States
- Volunteers
- 54,000 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Seasonal Influenza
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1010, and to evaluate relative vaccine efficacy (rVE) of mRNA-1010 versus an active comparator against reverse transcription polymerase…
- Trial name
- NCT06602024
- Testing
- mRNA-1010, Fluarix®, Influsplit® Tetra
- Where
- 301 sites in United States, Belgium and 9 more
- Volunteers
- 40,805 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Healthy Volunteers, Influenza
Study to Assess Safety and Immunogenicity of an Egg-based H5N8 Influenza Vaccine at Multiple Dose Levels Adjuvanted With Matrix-M in Healthy Participants 18 Years of Age and Above.
The study aims to evaluate an egg-based H5N8 influenza vaccine up to 3 dose levels (low, medium, and high dose) given with or without adjuvant to see if the adjuvant improves vaccine effectiveness.
- Trial name
- NCT07779408
- Testing
- Flu H5 egg pandemic low dose vaccine, with adjuvant, Flu H5 Egg Pandemic medium dose vaccine, with adjuvant, Flu H5 Egg Pandemic high dose vaccine, with adjuvant
- Where
- 16 sites in United States
- Volunteers
- 640 people, healthy volunteers welcome
- Sponsor
- Sanofi
Viral Pneumonia
Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Viral Infection
The goal of this Phase 2 study is to assess the safety, antiviral biomarker responses and efficacy of SNG001 when given to patients requiring invasive mechanical ventilation due to a respiratory virus infection.
- Trial name
- INVENT (NCT06999603)
- Testing
- SNG001
- Where
- 10 sites in United States, United Kingdom
- Volunteers
- 11 people
- Sponsor
- Synairgen Research Ltd.
Influenza, Human
Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in Adults
The goal of this clinical trial is to evaluate the safety and immune responses of three different dose levels a self-amplifying RNA pandemic influenza vaccine (ARCT-2304) in adults.
- Trial name
- NCT06602531
- Testing
- ARCT-2304, Control vaccine younger adults, Control vaccine older adults
- Where
- 4 sites in United States
- Volunteers
- 212 people, healthy volunteers welcome
- Sponsor
- Arcturus Therapeutics, Inc.
Influenza, Human
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age
This Phase 3 study is a randomized, observer-blind study of MF59-adjuvanted influenza vaccine (aQIV or aTIV) compared with a non-adjuvanted influenza vaccine (QIV or TIV) in adults ≥65 years of age.
- Trial name
- NCT06087640
- Testing
- aQIV or aTIV, QIV or TIV
- Where
- 255 sites in United States, Australia and 19 more
- Volunteers
- 38,769 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
A Study of SYH2085 Tablets Compared With Placebo in Chinese Adult Patients With Uncomplicated Influenza.
This is a multicenter, randomized, double-blind, placebo-controlled Phase II study to evaluate the efficacy and safety of SYH2085 tablets compared with placebo in Chinese adult participants with uncomplicated influenza.
- Trial name
- NCT07798193
- Testing
- SYH2085
- Volunteers
- 213 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Healthy Participants
A Study of Annual Doses of MK-1406/CD388 in Healthy Adults (MK-1406-006/CD388.SQ.2.07)
The goal of this clinical study is to learn if giving repeated annual doses of MK-1406 (CD388) is safe and how the body reacts to it in healthy adults who have already received one dose without serious side effects.
- Trial name
- NAVIGATE-2 (NCT07225959)
- Testing
- MK-1406 Injection
- Where
- 6 sites in United States, United Kingdom
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Influenza,Human, COVID-19
A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy People
This study is to learn about flu and COVID vaccines, either alone or when mixed together. Healthy people aged 18 or older can join. Participants will get one shot in each arm, either a flu or COVID vaccine, alone or mixed.
- Trial name
- NCT06683352
- Testing
- Investigational Influenza Vaccine, COVID-19 Vaccine, Investigational Influenza/COVID-19 Vaccine
- Where
- 22 sites in United States
- Volunteers
- 1,353 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Influenza
A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults
The purpose of this study is to evaluate humoral immunogenicity after 2 doses of mRNA-1018-H5, and to evaluate the safety and reactogenicity of mRNA-1018-H5 in adults ≥18 years of age.
- Trial name
- NCT07496450
- Testing
- mRNA-1018-H5
- Where
- 35 sites in United States, United Kingdom
- Volunteers
- 4,050 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Influenza Immunization, Healthy Volunteers
A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above
The purpose of this study was to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of different formulations of Quadrivalent Influenza Vaccine (QIV) messenger ribonucleic acid (mRNA) (MRT5421…
- Trial name
- NCT06361875
- Testing
- Quadrivalent Influenza mRNA Vaccine MRT5421, Quadrivalent Influenza mRNA Vaccine MRT5424, Quadrivalent Influenza mRNA Vaccine MRT5429
- Where
- 13 sites in United States, Honduras and 1 more
- Volunteers
- 908 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine
This Phase 1/2 study is intended to assess the safety, tolerability, and immunogenicity of recombinant TVLP in adults 18-64 and 65 years of age and above and to confirm the dose(s) to be developed further in these two age cohorts.
- Trial name
- NCT07291635
- Testing
- Recombinant Influenza vaccine candidate, Commercial Influenza vaccine
- Where
- 7 sites in Canada
- Volunteers
- 728 people, healthy volunteers welcome
- Sponsor
- Aramis Biotechnologies Inc.
Healthy Volunteer
Study of TRX-100 Evaluating the Safety, Pharmacokinetics, and Food Effect in Healthy Volunteers
This is a Phase 1b, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics, and food effect of single oral doses of TRX-100 tablets and capsules in healthy adult volunteers.
- Trial name
- NCT07526506
- Testing
- TRX-100
- Where
- Australia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Traws Pharma, Inc.
Influenza, Pandemic
A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Pandemic Flu Vaccine in Healthy Adults
The purpose of this clinical trial is to evaluate the safety and immunogenicity of BW-1014. BW-1014 is a nanoemulsion (NE) adjuvanted recombinant Hemagglutinin 5 (rH5) that would protect against pandemic flu.
- Trial name
- IN-NE-rH5 (NCT05397119)
- Testing
- BW-1014: 25 µg rH5 in 20% NE - pipette - IN, BW-1014: 50 µg rH5 in 20% NE - pipette - IN, BW-1014: 100 µg rH5 in 20% NE - pipette - IN
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- BlueWillow Biologics
Influenza, Human, Arthralgia
An Intravenous (IV) Zanamivir Pharmacokinetics (PK) Study in Hospitalized Neonates and Infants With Influenza Infection
Influenza infection is an important public health priority, with seasonal outbreaks and pandemics causing considerable global morbidity and mortality.
- Trial name
- NCT04494412
- Testing
- Zanamivir
- Where
- 6 sites in Italy, Poland and 1 more
- Volunteers
- 8 people
- Sponsor
- GlaxoSmithKline